OTLK vs. OMGA, BCAB, SGMO, LIFE, VXRT, DBVT, VIGL, BLUE, CRDL, and MOLN
Should you be buying Outlook Therapeutics stock or one of its competitors? The main competitors of Outlook Therapeutics include Omega Therapeutics (OMGA), BioAtla (BCAB), Sangamo Therapeutics (SGMO), aTyr Pharma (LIFE), Vaxart (VXRT), DBV Technologies (DBVT), Vigil Neuroscience (VIGL), bluebird bio (BLUE), Cardiol Therapeutics (CRDL), and Molecular Partners (MOLN). These companies are all part of the "biological products, except diagnostic" industry.
Outlook Therapeutics (NASDAQ:OTLK) and Omega Therapeutics (NASDAQ:OMGA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk, community ranking and dividends.
Outlook Therapeutics has higher earnings, but lower revenue than Omega Therapeutics. Outlook Therapeutics is trading at a lower price-to-earnings ratio than Omega Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Omega Therapeutics had 14 more articles in the media than Outlook Therapeutics. MarketBeat recorded 18 mentions for Omega Therapeutics and 4 mentions for Outlook Therapeutics. Omega Therapeutics' average media sentiment score of 0.40 beat Outlook Therapeutics' score of -0.03 indicating that Omega Therapeutics is being referred to more favorably in the news media.
Outlook Therapeutics has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, Omega Therapeutics has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500.
Outlook Therapeutics has a net margin of 0.00% compared to Omega Therapeutics' net margin of -3,147.92%. Omega Therapeutics' return on equity of -110.41% beat Outlook Therapeutics' return on equity.
Outlook Therapeutics received 132 more outperform votes than Omega Therapeutics when rated by MarketBeat users. However, 70.97% of users gave Omega Therapeutics an outperform vote while only 70.32% of users gave Outlook Therapeutics an outperform vote.
11.2% of Outlook Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Omega Therapeutics shares are held by institutional investors. 5.3% of Outlook Therapeutics shares are held by insiders. Comparatively, 57.0% of Omega Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Outlook Therapeutics currently has a consensus target price of $46.43, suggesting a potential upside of 482.50%. Omega Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 387.80%. Given Outlook Therapeutics' higher possible upside, equities research analysts plainly believe Outlook Therapeutics is more favorable than Omega Therapeutics.
Summary
Omega Therapeutics beats Outlook Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Outlook Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Outlook Therapeutics Competitors List
Related Companies and Tools
